5 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$227M | — | — | -$196M | $74M | $335M |
| 2024 | — | -$119M | — | — | -$117M | $0 | $180M |
| 2023 | — | -$36M | — | — | -$43M | — | $451M |
| 2022 | — | -$50M | — | — | -$56M | — | $40M |
| 2021 | — | -$5M | — | — | — | — | $8M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$70M | — | — | -$66M | $99M | $298M |
| Dec '25 | — | -$62M | — | — | -$59M | $74M | $335M |
| Sep '25 | — | -$70M | — | — | -$45M | $74M | $351M |
| Jun '25 | — | -$55M | — | — | -$55M | $73M | $307M |
| Mar '25 | — | -$40M | — | — | -$38M | $73M | $272M |
| Dec '24 | — | -$46M | — | — | -$49M | $0 | $180M |
| Sep '24 | — | -$35M | — | — | -$25M | — | $376M |
| Jun '24 | — | -$24M | — | — | -$28M | — | $343M |
| Mar '24 | — | -$14M | — | — | -$15M | — | $458M |
| Dec '23 | — | -$7M | — | — | -$13M | — | $451M |
| Sep '23 | — | -$9M | — | — | -$9M | — | $318M |
| Jun '23 | — | -$10M | — | — | -$12M | — | $502M |
| Mar '23 | — | -$9M | — | — | -$9M | — | $50M |
| Dec '22 | — | -$17M | — | — | -$12M | — | $40M |
| Sep '22 | — | -$10M | — | — | -$9M | — | $41M |
| Jun '22 | — | -$12M | — | — | -$21M | — | — |
| Mar '22 | — | -$16M | — | — | -$14M | — | $23336 |
| Dec '21 | — | -$2M | — | — | — | — | $8M |
| Sep '21 | — | -$6M | — | — | -$2M | — | $1M |
| Jun '21 | — | -$33M | — | — | — | — | $1M |
See the revenue and net-income charts above for Moonlake Immunotherapeutics's multi-year trend.
As of FY2025, Moonlake Immunotherapeutics reported $74M of total debt against $335M of cash; operating income covered interest expense -33.8×.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.